Overview
Safety risks are a major cause of attrition in drug discovery and development. A well designed and delivered toxicology package together with prompt and robust problem solving can make the difference between success and failure.
With advances in novel in vitro and in silico methodologies along with the greater understanding of the underlying mechanisms and biomarkers, discovery toxicology has emerged as a fundamental aspect of early stage R&D and is now recognized as a key step to build for success later in drug development.
This meeting will focus on new modalities in drug disocvery, and the strategies being used to support, and are being considered for implementation in early preclinical safety assessment.
Who should attend?
This one day meeting will showcase strategies that are enabling more efficient and robust approaches to achieve success in drug discovery and development.
This meeting will be of interest to colleagues from all aspects of drug discovery and related disciplines. The event is intended as a forum for all; from early stage researchers and industrial scientists right up to executive level managers. We encourage all of our delegates to bring their knowledge and experience to bear on the newest developments in Discovery and Development Toxicology.
For those interetsed to learn more of the reserach happening at Alderley Park, a campus tour will be taking place from 1.30-2.00 PM. Registartion for the tour should be made at the DiscoTox event desk.
Call for Abstracts: Posters & Poster Spotlights
Deadline for Abstracts Submission: 28th April
The conference committee has carefully selected the speaker line up for the day but welcome abstracts for poster presentations. There are a limited number of short 'poster spotlight' presentation opportunities available to high quality abstract submissions.
We encourage submissions researchers of all seniority levels from industry and academia. Any submissions from vendors must be application based and have scientific merit.
Please refer to the BTS Abstract Submission Guidance for guidelines on abstract format.
To submit an abstract please email your abstract with the subject ‘Discovery Tox Abstract’ to: abstracts@discotox.com for consideration. Please indicate if you wish to be considered for a a spotlight talk in addition to a poster presentation.
Early Career Scientist Bursaries
Bursaries available for UK and Europe based early career scientists.
To apply please email an abstract and 250 words on how the meeting will help develop your career with the subject ‘Discovery Tox Bursary’ to: abstracts@discotox.com
Closing date for application: May 20th 2023
Sponsor & Exhibitor Opportunities
There are opportunities to sponsor and/or exhibit at this event. Please get in touch for more information by emailing: Info@discotox.com
Venue, Travel & Accomodation
Find us at the Conference Centre, Alderley Park, SK10 STG
Food and refreshments will be provided to all delegates throughout the day. Please indicate an specific dietary requirements during registration.
For those driving, visitor parking will be available on site. Please refer to the Alderley Park Conference Centre Website for further information.
There are local accommodation options in nearby Alderley Edge, Macclesfield & Wilmslow should you require it. Please note, there is no affiliated accommodation options for the event. Please make your own arrangements.
Local Hotels :
- Alderley Edge Hotel | Hotel restaurant in Cheshire – Boutique hotel and restaurant (https://www.alderleyedgehotel.com/)
- De Trafford Arms Hotel | Alderley Edge | Official Website (greenekinginns.co.uk)
Both are in Alderley Edge and are equidistant from Alderley Park - 2 miles or 5 mins by car/taxi.
- Tytherington Club | Macclesfield (https://www.thetytheringtonclub.com/) - Mention you are attending Alderley Park for a discount on room rate
Macclesfield is approx. 20 mins by car to the venue
Conference Organising Committee
Ruth Roberts (Apconix)
Nicholas Coltman (Apconix)
Melanie Sakatis (GlaxoSmithKline)
Jamie Patient (Sygnature Discovery)
Carolin Schramm (British Toxicology Society)
Muireann Coen (British Toxicology Society/AstraZeneca)